Biogen Idec Inc (BIIB) 320.13 $BIIB
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report
Technical Snapshot on Biotech Stocks -- Research on Aegerion Pharma, Biogen Idec, Lexicon Pharma, and Curis
PR Newswire - Thu Jun 05, 7:30AM CDT
The US markets on Wednesday, June 4, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,737.53, up 0.09% and the NASDAQ Composite closed at 4,251.64, up 0.41%. The S&P 500 finished the session 0.19% higher at 1,927.88. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Biogen Idec Inc. (NASDAQ: BIIB), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) and Curis Inc. (NASDAQ: CRIS). Free technical research on AEGR, BIIB, LXRX and CRIS can be downloaded upon signing up at:
Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting.
Indolent Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sw248r/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Accentia Biopharmaceuticals, Inc. - Astellas Pharma Inc. - Bayer AG - Biogen Idec Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Merck & Co., Inc. - Merck KGaA - Pharmacyclics, Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/sw...t_lymphoma
Malignant Pleural Mesothelioma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82dd4m/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Boehringer Ingelheim GmbH - Biogen Idec Inc. - Merck & Co., Inc. - Oxford BioMedica plc - Novartis AG - Pfizer Inc. - Bionomics Limited - Synta Pharmaceuticals Corp. - Morphotek, Inc. - Virttu Biologics Limited - CanBas Co., Ltd. - MolMed S.p.A. - Genelux Corporation - Polaris Group - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/82...nt_pleural
Critical Alerts For Tesla, Apple, Ryder System, ExOne, and Biogen Idec Released By InvestorsObserver
PR Newswire - Tue Jun 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, AAPL, R, XONE, and BIIB.
Upcoming Shareholders Meeting, Multi-Choice Medical Plans, FDA Approvals, and Investor Conference Schedules - Analyst Notes on Biogen Idec, UnitedHealth Group, Amgen, WellPoint and Mylan
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc. (NASDAQ: AMGN), WellPoint Inc. (NYSE: WLP) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3241-100free.
Alexandria Real Estate Equities, Inc. Receives LEED Gold Certification for Biogen Idec Inc.'s Build-to-Suit Headquarters in Cambridge, Massachusetts
PR Newswire - Mon Jun 02, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an approximately $9 billion total market capitalization real estate investment trust (REIT) uniquely focused on clustering Class A assets in collaborative science and technology campuses in urban innovation centers, announced today that 225 Binney Street, an approximately 305,000 rentable-square-foot (RSF), world-class, build-to-suit headquarters space fully leased to Biogen Idec Inc. in Cambridge, Massachusetts, has achieved LEED® Gold Certification for Core and Shell from the US Green Building Council (USGBC). LEED, or Leadership in Energy & Environmental Design, recognizes best-in-class, innovative green building strategies, design, and construction practices. By granting this elite designation, the USGBC recognizes 225 Binney Street for its excellence in design, energy consumption, water efficiency, and environmental quality, affirming Alexandria's expertise in developing science and technology campuses at the forefront of sustainability and operational efficiency.
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Is This Really the Best Pipeline In Biotech?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 7:21PM CDT
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month....
Apple, Facebook, Valeant Among 5 Top IBD 50 Big Caps
at Investor's Business Daily - Fri May 30, 6:55PM CDT
Apple rocked the market with its purchase of Beats Electronics on Wednesday. But the personal electronics giant's shares have been on the uptick since reporting strong quarterly sales on April 23. Apple is among the top big-cap stocks on the IBD 50....
The Zacks Analyst Blog Highlights: Facebook, AT&T, Array BioPharma, Biogen Idec and Celgene
PR Newswire - Fri May 30, 8:40AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Facebook (Nasdaq:FB-Free Report), AT&T (NYSE:T-Free Report), Array BioPharma (Nasdaq:ARRY-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report) andCelgene Corp. (Nasdaq:CELG-Free Report).
Data from Biogen Idec's Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Business Wire - Fri May 30, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions.
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
No. 1 Draft Pick: Tremendous Upside or Total Bust?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Thu May 29, 3:38PM CDT
We love to answer reader questions, so send yours to HC@Fool.com. Here's a recent submission to our mailbag: The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your...
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Thu May 29, 12:20PM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Why Biogen Idec Inc. Shares Could Pop 20%
Brian Pacampara, The Motley Fool - Motley Fool - Thu May 29, 10:20AM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
Stock Market News for June 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 9:06AM CDT
Benchmarks erased day’s initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report
Technical Snapshot on Biotech Stocks -- Research on Aegerion Pharma, Biogen Idec, Lexicon Pharma, and Curis
PR Newswire - Thu Jun 05, 7:30AM CDT
The US markets on Wednesday, June 4, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,737.53, up 0.09% and the NASDAQ Composite closed at 4,251.64, up 0.41%. The S&P 500 finished the session 0.19% higher at 1,927.88. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), Biogen Idec Inc. (NASDAQ: BIIB), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) and Curis Inc. (NASDAQ: CRIS). Free technical research on AEGR, BIIB, LXRX and CRIS can be downloaded upon signing up at:
Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting.
Indolent Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sw248r/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Accentia Biopharmaceuticals, Inc. - Astellas Pharma Inc. - Bayer AG - Biogen Idec Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Merck & Co., Inc. - Merck KGaA - Pharmacyclics, Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/sw...t_lymphoma
Malignant Pleural Mesothelioma - Pipeline Review, H1 2014
M2 - Wed Jun 04, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82dd4m/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Boehringer Ingelheim GmbH - Biogen Idec Inc. - Merck & Co., Inc. - Oxford BioMedica plc - Novartis AG - Pfizer Inc. - Bionomics Limited - Synta Pharmaceuticals Corp. - Morphotek, Inc. - Virttu Biologics Limited - CanBas Co., Ltd. - MolMed S.p.A. - Genelux Corporation - Polaris Group - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/82...nt_pleural
Critical Alerts For Tesla, Apple, Ryder System, ExOne, and Biogen Idec Released By InvestorsObserver
PR Newswire - Tue Jun 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, AAPL, R, XONE, and BIIB.
Upcoming Shareholders Meeting, Multi-Choice Medical Plans, FDA Approvals, and Investor Conference Schedules - Analyst Notes on Biogen Idec, UnitedHealth Group, Amgen, WellPoint and Mylan
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc. (NASDAQ: AMGN), WellPoint Inc. (NYSE: WLP) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3241-100free.
Alexandria Real Estate Equities, Inc. Receives LEED Gold Certification for Biogen Idec Inc.'s Build-to-Suit Headquarters in Cambridge, Massachusetts
PR Newswire - Mon Jun 02, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an approximately $9 billion total market capitalization real estate investment trust (REIT) uniquely focused on clustering Class A assets in collaborative science and technology campuses in urban innovation centers, announced today that 225 Binney Street, an approximately 305,000 rentable-square-foot (RSF), world-class, build-to-suit headquarters space fully leased to Biogen Idec Inc. in Cambridge, Massachusetts, has achieved LEED® Gold Certification for Core and Shell from the US Green Building Council (USGBC). LEED, or Leadership in Energy & Environmental Design, recognizes best-in-class, innovative green building strategies, design, and construction practices. By granting this elite designation, the USGBC recognizes 225 Binney Street for its excellence in design, energy consumption, water efficiency, and environmental quality, affirming Alexandria's expertise in developing science and technology campuses at the forefront of sustainability and operational efficiency.
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Is This Really the Best Pipeline In Biotech?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 7:21PM CDT
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month....
Apple, Facebook, Valeant Among 5 Top IBD 50 Big Caps
at Investor's Business Daily - Fri May 30, 6:55PM CDT
Apple rocked the market with its purchase of Beats Electronics on Wednesday. But the personal electronics giant's shares have been on the uptick since reporting strong quarterly sales on April 23. Apple is among the top big-cap stocks on the IBD 50....
The Zacks Analyst Blog Highlights: Facebook, AT&T, Array BioPharma, Biogen Idec and Celgene
PR Newswire - Fri May 30, 8:40AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Facebook (Nasdaq:FB-Free Report), AT&T (NYSE:T-Free Report), Array BioPharma (Nasdaq:ARRY-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report) andCelgene Corp. (Nasdaq:CELG-Free Report).
Data from Biogen Idec's Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Business Wire - Fri May 30, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions.
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
No. 1 Draft Pick: Tremendous Upside or Total Bust?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Thu May 29, 3:38PM CDT
We love to answer reader questions, so send yours to HC@Fool.com. Here's a recent submission to our mailbag: The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your...
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Thu May 29, 12:20PM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Why Biogen Idec Inc. Shares Could Pop 20%
Brian Pacampara, The Motley Fool - Motley Fool - Thu May 29, 10:20AM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
